Aquestive Therapeutics, Inc. (AQST) Free cash flow 2017–2025
Aquestive Therapeutics, Inc. (AQST) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$53.0MFY2025 · since FY2017: $3.8M → -$53.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$53.0M | -47.5% |
| FY2024 | -$35.9M | -387.0% |
| FY2023 | -$7.4M | +32.0% |
| FY2022 | -$10.8M | +68.0% |
| FY2021 | -$33.9M | +26.3% |
| FY2020 | -$46.0M | +24.5% |
| FY2019 | -$60.9M | -310.9% |
| FY2018 | -$14.8M | -494.4% |
| FY2017 | $3.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More AQST financial trends
AQST RevenueAQST Net incomeAQST Net marginAQST Gross profitAQST Gross marginAQST Operating incomeAQST Operating marginAQST Operating cash flowAQST Capital expendituresAQST Return on equityAQST Stock buybacksAQST Dividends paidAQST Total assetsAQST Total liabilitiesAQST Shareholders’ equityAQST overview →